Colorectal carcinomas: A total of 306 CRC samples were analyzed and in all of them the clinician requested the analysis of KRAS and NRAS. Eight CRC samples (2.6%) could not be assessed due to the lack of amplifiable DNA (Table 4, Figure 3). This evidence concerns the gene NRAS and colorectal carcinoma.